Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 1/2010

01-02-2010

Sleep Duration and the Risk of Diabetes Mellitus: Epidemiologic Evidence and Pathophysiologic Insights

Authors: Ferdinand Zizi, Girardin Jean-Louis, Clinton D. Brown, Gbenga Ogedegbe, Carla Boutin-Foster, Samy I. McFarlane

Published in: Current Diabetes Reports | Issue 1/2010

Login to get access

Abstract

Evidence from well-defined cohort studies has shown that short sleep, through sleep fragmentation caused by obstructive sleep apnea (OSA) or behavioral sleep curtailment because of lifestyle choices, is associated with increased incidence of diabetes. In this report, we review epidemiologic and clinical data suggesting that OSA is involved in the pathogenesis of altered glucose metabolism. Evidence suggesting increased risk of developing diabetes resulting from curtailed sleep duration is also considered. Proposed mechanisms explaining associations between short sleep and diabetes are examined and clinical management of OSA among patients with diabetes is discussed.
Literature
1.
Kripke DF, Garfinkel L, Wingard DL, et al.: Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002, 59:131–136.CrossRefPubMed
2.
Patel SR, Ayas NT, Malhotra MR, et al.: A prospective study of sleep duration and mortality risk in women. Sleep 2004, 27:440–444.PubMed
3.
Tamakoshi A, Ohno Y: Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC study, Japan. Sleep 2004, 27:51–54.PubMed
4.
National Sleep Foundation: Sleep in American Poll. Washington, DC: National Sleep Foundation; 2008.
5.
Jean-Louis G, Kripke DF, Ancoli-Israel S, et al.: Sleep duration, illumination, and activity patterns in a population sample: effects of gender and ethnicity. Biol Psychiatry 2000, 47:921–927.CrossRefPubMed
6.
Harris MI: Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998, 21(Suppl 3):C11–C14.PubMed
7.
Gottlieb DJ, Punjabi NM, Newman AB, et al.: Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 2005, 165:863–867.CrossRefPubMed
8.
Punjabi NM, Polotsky VY: Disorders of glucose metabolism in sleep apnea. Association of sleep time with diabetes mellitus and impaired glucose tolerance. J Appl Physiol 2005, 99:1998–2007.CrossRefPubMed
9.
Jemal A, Ward E, Hao Y, Thun M: Trends in the leading causes of death in the United States, 1970–2002. JAMA 2005, 294:1255–1259.CrossRefPubMed
10.
Young T, Finn L: Epidemiological insights into the public health burden of sleep disordered breathing: sex differences in survival among sleep clinic patients. Thorax 1998, 53(Suppl 3):S16–S19.CrossRefPubMed
11.
Young T, Peppard P: Sleep-disordered breathing and cardiovascular disease: epidemiologic evidence for a relationship. Sleep 2000, 23(Suppl 4):S122–S126.PubMed
12.
Young T, Peppard P, Palta M, et al.: Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997, 157:1746–1752.CrossRefPubMed
13.
Hiestand DM, Britz P, Goldman M, et al.: Prevalence of symptoms and risk of sleep apnea in the US population: results from the national sleep foundation sleep in America 2005 poll. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Chest 2006, 130:780–786.CrossRefPubMed
14.
15.
Patil SP, Schneider H, Schwartz AR, Smith PL: Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest 2007, 132:325–337.CrossRefPubMed
16.
Pinto JM, Garpestad E, Weiss JW, et al.: Hemodynamic changes associated with obstructive sleep apnea followed by arousal in a porcine model. J Appl Physiol 1993, 75:1439–1443.PubMed
17.
Somers VK, Dyken ME, Clary MP, Abboud FM: Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995, 96:1897–1904.CrossRefPubMed
18.
Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540–545.PubMed
19.
El Ad B, Lavie P: Effect of sleep apnea on cognition and mood. Int Rev Psychiatry 2005, 17:277–282.CrossRefPubMed
20.
Guilleminault C, Stoohs R, Clerk A, et al.: A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993, 104:781–787.CrossRefPubMed
21.
Kiely JL, McNicholas WT, Zgierska A, et al.: Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000, 16:128–133.CrossRefPubMed
22.
Wright J, Johns R, Watt I, et al.: Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence. BMJ 1997, 314:851–860.PubMed
23.
Findley LJ, Weiss JW, Jabour ER: Drivers with untreated sleep apnea. A cause of death and serious injury. Arch Intern Med 1991, 151:1451–1452.CrossRefPubMed
24.
Newman AB, Nieto FJ, Guidry U, et al.: Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001, 154:50–59.CrossRefPubMed
25.
Stoohs RA, Guilleminault C, Itoi A, Dement WC: Traffic accidents in commercial long-haul truck drivers: the influence of sleep-disordered breathing and obesity. Sleep 1994, 17:619–623.PubMed
26.
Lavie P, Herer P, Peled R, et al.: Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 1995, 18:149–157.PubMed
27.
Spiegel R, Knudtson K, Leproult R, et al.: Sleep loss: a novel risk factor for insulin resistance and type II diabetes. J Appl Physiol 2005, 99:2008–2019.CrossRefPubMed
28.
Spiegel K, Leproult R, Van Cauter E: Impact of sleep debt on metabolic and endocrine function. Lancet 1999, 354:1435–1439.CrossRefPubMed
29.
Punjabi NM, Sorkin JD, Katzel LI, et al.: Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002, 165:677–682.PubMed
30.
Vgontzas AN, Papanicolaou DA, Bixler EO, et al.: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000, 85:1151–1158.CrossRefPubMed
31.
Young T, Peppard PE, Taheri S: Excess weight and sleep-disordered breathing. J Appl Physiol 2005, 99:1592–1599.CrossRefPubMed
32.
Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al.: Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002, 105:2462–2464.CrossRefPubMed
33.
Punjabi NM, Ahmed MM, Polotsky VY, et al.: Sleep-disordered breathing, glucose intolerance, and insulin resistance. Respir Physiol Neurobiol 2003, 136:167–178.CrossRefPubMed
34.
Punjabi NM, Shahar E, Redline S, et al.: Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004, 160:521–530.CrossRefPubMed
35.
Reichmuth KJ, Austin D, Skatrud JB, Young T: Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005, 172:1590–1595.CrossRefPubMed
36.
Ayas NT, White DP, Al Delaimy WK, et al.: A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 2003, 26:380–384.CrossRefPubMed
37.
• Beihl DA, Liese AD, Haffner SM: Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol 2009, 19:351–357. This is a study that assessed associations between sleep duration and type 2 diabetes, considering insulin sensitivity and secretion, two important risk factors for diabetes.
38.
Ayas NT, White DP, Manson JE, et al.: A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 2003, 163:205–209.CrossRefPubMed
39.
Mallon L, Broman JE, Hetta J: High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. Diabetes Care 2005, 28:2762–2767.CrossRefPubMed
40.
Nilsson PM, Roost M, Engstrom G, et al.: Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 2004, 27:2464–2469.CrossRefPubMed
41.
•• Gangwisch JE, Heymsfield SB, Boden-Albala B, et al.: Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007, 30:1667–1673. This study explored relationships between sleep duration and diabetes incidence over an 8- to 10-year follow-up period in data from the First National Health and Nutrition Examination Survey.
42.
Sanders MH, Givelber R: Sleep disordered breathing may not be an independent risk factor for diabetes, but diabetes may contribute to the occurrence of periodic breathing in sleep. Sleep Med 2003, 4:349–350.CrossRefPubMed
43.
Zizi F, Jean-Louis G, Fernandez S, et al.: Sleep duration and risk of diabetes: analysis of the National Health Interview Survey [abstract]. Sleep 2009, 32:152.
44.
Mezuk B, Eaton WW, Albrecht S, Golden SH: Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31:2383–2390.CrossRefPubMed
45.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069–1078.CrossRefPubMed
46.
Knol MJ, Twisk JW, Beekman AT, et al.: Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006, 49:837–845.CrossRefPubMed
47.
Edinger JD, Hoelscher TJ, Marsh GR, et al.: A cognitive-behavioral therapy for sleep-maintenance insomnia in older adults. Psychol Aging 1992, 7:282–289.CrossRefPubMed
48.
Edinger JD, Carwile S, Miller P, et al.: Psychological status, syndromatic measures, and compliance with nasal CPAP therapy for sleep apnea. Percept Mot Skills 1994, 78:1116–1118.PubMed
49.
50.
• Dorkova Z, Petrasova D, Molcanyiova A, et al.: Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008, 134:686–692. This study examined the effects of 8 weeks of continuous positive airway pressure therapy on glucose and lipid profile, systemic inflammation, oxidative stress, and global cardiovascular disease risk among patients with OSA and metabolic syndrome.
51.
Babu AR, Herdegen J, Fogelfeld L, et al.: Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005, 165:447–452.CrossRefPubMed
52.
McNicholas WT, Javaheri S: Pathophysiologic mechanisms of cardiovascular disease in obstructive sleep apnea. Sleep Med Clin 2007, 2:539–547.CrossRef
53.
Jean-Louis G, Zizi F, Clark LT, Kossotis J: Associations of sleep apnea to cardiovascular diseases: role of diabetes and metabolic syndrome. In In Cardiovascular Disease and Diabetes: Contemporary Management. Edited by Clark LT. New York: McGraw-Hill; 2007:472–505.
Metadata
Title
Sleep Duration and the Risk of Diabetes Mellitus: Epidemiologic Evidence and Pathophysiologic Insights
Authors
Ferdinand Zizi
Girardin Jean-Louis
Clinton D. Brown
Gbenga Ogedegbe
Carla Boutin-Foster
Samy I. McFarlane
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 1/2010
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-009-0082-x

Other articles of this Issue 1/2010

Current Diabetes Reports 1/2010 Go to the issue

Clinical Trial Report

Relationship of Coronary Angiographic Findings to Choice of Antidiabetic Medication

Invited Commentary

Challenges and Approaches to Managing Type 2 Diabetes Mellitus

Clinical Trial Report

Strategies to Achieve Target LDL Levels

OriginalPaper

When Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?

OriginalPaper

Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes

OriginalPaper

The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits